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Synovial DKK1 expression is regulated by
local glucocorticoid metabolism in
inflammatory arthritis
Rowan Hardy1, Maria Juarez2, Amy Naylor2, Jinwen Tu3, Elizabeth H Rabbitt1, Andrew Filer2, Paul M Stewart1,
Christopher D Buckley2,4, Karim Raza2,4† and Mark S Cooper1*†
Abstract
Introduction: Inflammatory arthritis is associated with increased bone resorption and suppressed bone formation.
The Wnt antagonist dickkopf-1 (DKK1) is secreted by synovial fibroblasts in response to inflammation and this
protein has been proposed to be a master regulator of bone remodelling in inflammatory arthritis. Local
glucocorticoid production is also significantly increased during joint inflammation. Therefore, we investigated how
locally derived glucocorticoids and inflammatory cytokines regulate DKK1 synthesis in synovial fibroblasts during
inflammatory arthritis.
Methods: We examined expression and regulation of DKK1 in primary cultures of human synovial fibroblasts
isolated from patients with inflammatory arthritis. The effect of TNFa, IL-1b and glucocorticoids on DKK1 mRNA
and protein expression was examined by real-time PCR and ELISA. The ability of inflammatory cytokine-induced
expression of the glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) to
sensitise fibroblasts to endogenous glucocorticoids was explored. Global expression of Wnt signalling and target
genes in response to TNFa and glucocorticoids was assessed using a custom array.
Results: DKK1 expression in human synovial fibroblasts was directly regulated by glucocorticoids but not
proinflammatory cytokines. Glucocorticoids, but not TNFa, regulated expression of multiple Wnt agonists and
antagonists in favour of inhibition of Wnt signalling. However, TNFa and IL-1b indirectly stimulated DKK1
production through increased expression of 11b-HSD1.
Conclusions: These results demonstrate that in rheumatoid arthritis synovial fibroblasts, DKK1 expression is directly
regulated by glucocorticoids rather than TNFa. Consequently, the links between synovial inflammation, altered Wnt
signalling and bone remodelling are not direct but are dependent on local activation of endogenous
glucocorticoids.
Introduction
During adult life, bone formation and resorption are nor-
mally tightly coupled such that the amount of bone
formed is similar to the amount resorbed. However, in
patients with chronic inflammatory arthritis (for example,
rheumatoid arthritis (RA)) bone remodelling is abnormal
[1,2]. Bone resorption is increased due to increased activ-
ity of osteoclasts whereas bone formation by osteoblasts
is suppressed. The uncoupling of formation from resorp-
tion results in bone loss and an increased risk of fractures
[3]. A similar process is seen in states of systemic gluco-
corticoid excess such as Cushing’s syndrome or during
treatment with therapeutic glucocorticoids, but circulat-
ing glucocorticoid levels in patients with RA are not
elevated [4]. We have previously hypothesised that the
bone loss seen in inflammatory arthritis is secondary
to local glucocorticoid activation through the 11beta-
hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme
[5]. This enzyme converts inactive steroids (such as corti-
sone and prednisone) to their active counterparts (cortisol
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and prednisolone) [6,7]. Patients lacking this enzyme are
unresponsive to cortisone acetate or prednisone therapy
due to their inability to activate these steroids in vivo [8].
We have previously demonstrated that this enzyme is
highly expressed in human primary synovial fibroblasts
and synovial tissue explants [9,10]. In vitro, the expression
and activity of this enzyme increase dramatically in these
cells and tissues in response to TNFa or IL-1b [9-11]. In
patients with RA, 11b-HSD1 activity in synovial tissue and
total body measures of 11b-HSD1 activity are increased
and correlate with serum markers of inflammation [10]. In
a rodent model of inflammatory arthritis, 11b-HSD1 activ-
ity and expression in the joint are increased, and activity is
reduced by anti-TNF therapy [12]. Thus the level of active
glucocorticoids within the joint, and specifically within
synovial fibroblasts, appears to be high during inflamma-
tory arthritis.
Recently, secretion of the Wnt antagonist dickkopf-1
(DKK1) has been proposed to be a master regulator of
bone remodelling in inflammatory arthritis [13]. DKK1
suppresses osteoblast differentiation but also decreases
the expression of osteoprotegerin (OPG) leading to
increased osteoclastogenesis. DKK1 is synthesised by
murine synovial fibroblasts in response to inflammation
through a TNFa-dependent mechanism [13]. Neutralisa-
tion of DKK1 in mice using anti-DKK1 antibodies
reversed the bone loss seen in inflammatory arthritis and
resulted in the formation of new bone near the areas of
greatest inflammation. In osteoblasts, mesenchymal cells
that are developmentally closely related to synovial fibro-
blasts, glucocorticoids are a very powerful inducer of
DKK1 and this effect has been proposed as the mechan-
ism that mediates bone loss due to systemic glucocorti-
coid excess [14]. Given the increase in 11b-HSD1
expression that we have observed in synovial fibroblasts,
we hypothesised that the regulation of synovial fibroblast
DKK1 expression by inflammation was indirect and
dependent on the local generation of glucocorticoids
within the synovial fibroblasts. Therefore, we assessed
the regulation and relative expression of DKK1 following
treatments with both glucocorticoids and inflammatory
cytokines in primary synovial fibroblasts.
Materials and methods
Patients
Biopsies of matched synovium and skin were obtained
during hip, knee or elbow arthroplasty from patients with
RA (based on the 1987 American College of Rheumatol-
ogy (formally the American Rheumatism Association)
criteria), osteoarthritis (OA) and ankylosing spondylitis
(AS) (based on the modified New York criteria). Tissue
was taken on ice from the operating theatre and synovial
tissue was prepared within 2 hours by removing any
adherent non-synovial tissue. Tissue explant experiments
were performed on 20 mg sections prior to enzyme assay
or ELISA. Skin tissue was prepared by removing the sub-
cutaneous fat and dividing into 20 mg pieces prior to
enzyme assay or ELISA. Primary cultures of synovial and
dermal fibroblasts were generated as described previously
[9]. Fibroblasts were treated with 0.01 to 10 ng/ml TNFa
(R&D Systems, Abingdon, UK) or 0.1 to 100 nmol/l of
dexamethasone (DEX), cortisol or cortisone with or with-
out 1 μmol/l of the 11b-HSD inhibitor glycyrrhetinic acid
(GE) for 24 hours before harvesting for mRNA analysis
or for 48 hours before measuring DKK1 in culture media.
All studies had ethical approval from the Local Ethics
Committee and informed consent was obtained prior to
taking of samples.
RNA extraction and reverse transcription
RNA was extracted from cultured fibroblasts using the
single-step extraction method (TRI Reagent, Sigma-
Aldrich, Poole, UK). Briefly, confluent monolayers of syno-
vial fibroblasts in 6-well plates were lysed in 1 ml of TRI
Reagent and RNA isolated as per the manufacturers proto-
col. RNA were then reverse transcribed using random
hexamers in a 20 μl volume, as stated in the manufac-
turer’s protocol (Promega, Madison, WI, USA) [15].
Real-time PCR
Probes and primers were based on Assay-on-Demand™
sequences (Applied Biosystems, Warrington, UK).
mRNA levels for DKK1 (Hs00183740_m1), DKK2
(Hs00997455_m1), WNT2 (Hs00608224_m1) and FRZB
(Hs00173503_m1) were assessed using real-time PCR in
an ABI 7500 system (Applied Biosystems, Warrington,
UK) using a previously reported technique [11]. Reac-
tions contained TaqMan universal PCR master mix
(Applied Biosystems, Warrington, UK), 900 nmol pri-
mers, 100 to 200 nmol TaqMan probe and 50 ng
cDNA. Primers for 18S (Hs03928985_g1) were used as
an internal reference. All target gene probes were
labelled with the fluorescent label FAM, and the 18S
probe with the fluorescent label VIC. Reactions occurred
as follows: 50°C for 2 minutes, 95°C for 10 minutes, 40
cycles of 95°C for 15 seconds and 60°C for 1 minute.
Data were obtained as Ct values (the cycle number at
which logarithmic PCR plots cross a calculated thresh-
old line) and used to determine ΔCt values (Ct of target
gene - Ct of housekeeping gene) as raw data for gene
expression (high ΔCt = low gene expression). The fold
change in gene expression was determined by subtract-
ing ΔCt values for treated cells from their respective
control samples. The resulting ΔΔCt values were then
used to calculate fold change in gene expression accord-
ing to the equation 2-ΔΔCt.
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Real-time PCR custom TaqMan gene array
Global expression of Wnt signalling and target genes
was assessed using the predefined Wnt signalling gene
format with TaqMan Express Plates (Catalogue number
4391524, Applied Biosystems, Warrington, UK). Both
18S and GAPDH were used as an internal reference.
FAM-labelled primers and probes were reconstituted to
20 μl in TaqMan universal PCR master mix (Applied
Biosystems, Warrington, UK) containing 50 ng of target
cDNA. Real-time PCR was performed using an ABI
7500 system (Applied Biosystems, Warrington, UK)
using a previously reported technique [11]. Reaction
conditions and data analysis were performed as reported
for real-time PCR. Array data were submitted to the
Gene Expression Omnibus (GEO) repository and given
the designation GSE37520.
Analysis of DKK1 levels by ELISA
DKK1 levels in supernatants from cultured cells were
measured using a commercially available sandwich
ELISA (Catalogue Number: DY1906, R&D systems,
Abingdon, UK). Briefly, synovial fibroblasts were seeded
at 100,000 cells per well in a 6-well plate. Media was con-
ditioned for 48 hours in the presence or absence of
appropriate treatments. Conditioned media was collected
and stored at -80°C prior to analysis in triplicate by
ELISA. Data were expressed as ng/ml of DKK1 in culture
media after 48 hour culture with 100,000 cells from a
minimum of three separate fibroblast lines.
Statistics
Data were reported as the mean ± standard deviation
(SD) of synovial explants from separate individuals
(unless otherwise stated). Multiple comparisons were
assessed using one-way ANOVA with a Dunnett’s post
hoc analysis. Regression analysis and students paired t
tests were performed using SPSS Data Editor (SPSS Inc.,
Chicago, IL, USA).
Results
Induction of DKK1 expression in human primary synovial
fibroblasts is by glucocorticoids and not TNFa/IL-1b
The effects of glucocorticoids and proinflammatory cyto-
kines on DKK1 expression were examined in primary
human synovial fibroblasts. Dexamethasone (100 nM)
caused a substantial and statistically significant increase in
DKK1 mRNA expression (4.9-fold vs control; P < 0.05)
(Figure 1A). TNFa (10 ng/ml) caused a small and non-sig-
nificant increase in DKK1 mRNA expression (2.3-fold vs
control; NS). In this experimental set-up, levels of endo-
genous glucocorticoids in the media were below those
required to allow an indirect glucocorticoid-mediated
effect of TNFa expression on DKK1 mRNA expression.
TNFa did not further augment the effect of glucocorticoid
treatment on DKK1 mRNA expression when the two were
combined. Similar results were obtained when the effect of
dexamethasone on DKK1 mRNA expression was com-
pared with IL-1b (10 ng/mL) (Figure 1B) with IL-1b hav-
ing no direct effect on DKK1 mRNA expression. There
was no effect of dexamethasone, TNFa or IL-1b treatment
on DKK1 mRNA expression in dermal fibroblasts that
were used as non-synovial, fibroblast controls. Dexametha-
sone also caused a significant increase in DKK1 protein
secretion in synovial fibroblast cultures but TNFa and
IL-1b had no overall effect (control, 4.4 ± 0.4 vs DEX,
12.3 ± 0.4 ng/ml; P < 0.05) (Figure 1C).
The time course of DKK1 secretion in response to dexa-
methasone is shown in Figure 2A. DKK-1 expression
increased in a time-dependent manner. There was no
increase in DKK1 secretion with TNFa above basal
expression at any time point, whilst dexamethasone signif-
icantly increased expression at all time points examined
(48 hour control, 18.6 ± 2.8 ng/ml vs 48 hour DEX, 34.5 ±
1.8 ng/ml; P < 0.05). The expression of DKK1 in response
to dexamethasone was dose dependent and reached a
peak at 100 nM dexamethasone (control, 1 ± 1.1 ng/ml vs
DEX 100 nmol/l, 6.0 ± 1.4 ng/ml; P < 0.05) (Figure 2B). In
contrast, TNFa and IL-1b at any dose did not significantly
increase secreted DKK1 in dose-response experiments
(Figure 2C-D).
Activation of glucocorticoids within synovial fibroblasts
regulates DKK1 synthesis
Since dexamethasone is a synthetic glucocorticoid, we
further examined whether endogenous glucocorticoids
also have the same effect on DKK1 expression (Figure 3).
The effect of cortisol was similar to that of dexametha-
sone in inducing DKK1 mRNA and protein expression
(DEX; mRNA 3.1-fold, protein 2.7-fold ± 0.53; cortisol,
mRNA 3.2-fold, protein 2.3-fold ± 0.39 vs control; P <
0.05) (Figure 3A and 3B). Cortisone was also found to
significantly induce DKK1 mRNA and protein expression
(cortisone; mRNA 2.7-fold, protein 1.6-fold ± 1.8 vs con-
trol; P < 0.05). To function effectively as a glucocorticoid
receptor agonist, cortisone needs to be converted to cor-
tisol by the 11b-HSD1 enzyme [4]. Inhibition of the 11b-
HSD1 enzyme using glycyrrhetinic acid (GE) blocked the
effect of cortisone on DKK1 expression. As observed for
dexamethasone, neither cortisol nor cortisone had an
impact on DKK1 expression in dermal fibroblasts (data
not shown). Given the lack of direct induction of DKK1
expression with TNFa, we explored whether TNFa treat-
ment could sensitise synovial fibroblasts to cortisone
through induction of 11b-HSD1 activity (Figure 3C). The
duration of incubation of synovial fibroblasts with corti-
sone was reduced to 5 hours, such that conversion of
cortisone to cortisol was insufficient to have any effect on
DKK1 protein synthesis under basal conditions. Under
Hardy et al. Arthritis Research & Therapy 2012, 14:R226
http://arthritis-research.com/content/14/5/R226
Page 3 of 9
these conditions, pretreatment with TNFa sensitised
synovial fibroblasts to the effects of cortisone. This effect
was blocked by an inhibitor of 11b-HSD1 activity, con-
firming an indirect effect of TNFa via upregulation of
11b-HSD1 activity.
Comparison between DKK1 synthesis in patients with RA,
OA and AS
To assess whether the changes observed were specific
to synovial fibroblasts of RA origin, the effect of
glucocorticoids on DKK1 protein secretion was exam-
ined in synovial fibroblasts isolated from patients with
different arthritides (OA and AS, n = 5 in total). As
with synovial fibroblasts from patients with RA, both
cortisol and cortisone were able to induce DKK1 synth-
esis (data not shown). There was a suggestion that the
basal expression level of DKK1 was lower in patients
with AS (P < 0.05 when AS cells were compared to
other synovial fibroblasts) but the number of patients
with AS limited the robustness of this finding.
Figure 1 Effects of glucocorticoids/proinflammatory cytokines on DKK1 expression in primary synovial fibroblasts (FLS) or dermal fibroblasts
(DF). Results shown are the combined duplicates of four separate FLS or DF cell-lines. (A) Effect of dexamethasone (100 nM), TNFa (10 ng/ml), or (B)
IL-1b (10 ng/ml) on DKK1 mRNA expression in FLS. (C) Effect of dexamethasone (100 nM), TNFa (10 ng/ml) and IL-1b (10 ng/ml) on secretion of DKK1
protein in FLS. Dexamethasone but not TNFa or IL-1b, induces significant secretion of DKK1 protein from FLS. *P < 0.05, **P < 0.01.
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Glucocorticoids modify Wnt gene expression within
synovial fibroblasts in a coordinated manner
The effect of glucocorticoid treatment (100 nM dexa-
methasone) or TNFa (10 ng/ml) on expression of a
range of Wnt-related genes (n = 96) was examined using
a targeted microarray (a full list of the genes included in
the array is given in Additional file 1, Table S1 and data
can be found at the GEO repository with reference num-
ber GSE37520). Genes with the greatest fold change are
shown in Figure 4. In keeping with the results shown ear-
lier, glucocorticoid treatment resulted in a significant
increase in DKK1 expression (3.1-fold vs control; P <
0.05). There was, in addition, a substantial induction of
the frizzled-related protein-B (FRZB) gene (also known
as secreted frizzled related protein-3 (SFRP3)) (10.6-fold
vs control; P < 0.05). FRZB, like DKK1, is also a secreted
inhibitor of Wnt signalling. In keeping with a coordi-
nated effect to reduce Wnt signalling, the expression of
WNT2 was substantially reduced (7.2-fold vs control; P <
0.05). The effect of TNFa on expression of Wnt-related
genes was less dramatic and did not suggest a coordi-
nated effect on the expression of secreted Wnts and their
antagonists. The genes with greatest upregulation in
response to TNFa treatment were the ubiquitin-like gene
UBD and cyclooxygenase-2 (PTGS2) (59.4- and 8.3-fold
respectively; P < 0.05). TNFa had no significant effect on
DKK1 and FRZB expression. Real-time PCR was used
to validate the changes in mRNA expression for FRZB
and WNT2 in response to dexamethasone and TNFa
(Figure 4C).
Discussion
Bone is an important target tissue in patients with RA,
with many patients developing local erosions and periarti-
cular and generalised osteoporosis. Previous studies have
highlighted the central importance of synovial fibroblasts
in the abnormal bone remodelling associated with joint
inflammation [13]. These effects were assumed to be due
to direct effects of inflammatory mediators, principally on
expression of the Wnt signalling antagonist DKK1. Indeed,
a growing body of work has demonstrated that this
secreted factor is markedly elevated in the serum of
patients with rheumatoid arthritis, where its levels posi-
tively correlate with multiple markers of disease activity
[13,16]. Most importantly, DKK1 positively correlated
with erosive bone loss in patients with rheumatoid
Figure 2 Regulation of DKK1 expression by glucocorticoids. (A) Time course for induction of DKK1 protein expression by synovial fibroblasts
(FLS) in response to dexamethasone or TNFa. (B) Dose response curves for the secretion of DKK1 in response to dexamethasone (expressed
relative to baseline expression). *P < 0.05, **P < 0.01 relative to control.
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arthritis, supporting a central role for this factor in inflam-
matory bone loss. Our findings demonstrate that the effect
of inflammation on DKK1 synthesis is not direct, but
instead depends on an increase in local glucocorticoid
levels through the induction of the 11b-HSD1 enzyme
(illustrated schematically in Figure 5). High levels of gluco-
corticoids are linked with a range of conditions that detri-
mentally affect bone through uncoupling bone formation
from resorption, but this is the first study to show a link
between effects of glucocorticoids on synovial tissue and
uncoupling of bone metabolism through a paracrine effect.
Glucocorticoids also cause a coordinated change in pro-
duction of Wnt signalling modulators by synovial fibro-
blasts that extends beyond DKK1 with an increase in
several antagonists and a suppression of agonists. These
findings are in accordance with the effects of glucocorti-
coids on Wnt production by osteoblasts [14], a cell type
closely related developmentally to the synovial fibroblast.
It is well established that high circulating levels of endo-
genous or exogenous glucocorticoids suppress bone for-
mation. This is at least partly through a direct mechanism,
since mice with osteoblast-specific deletion of the gluco-
corticoid receptor alpha (GRa) or overexpression of 11b-
HSD2 (which inactivates glucocorticoids) within osteo-
blasts are protected against the effects of high-dose gluco-
corticoids on bone [17,18]. These results suggest that the
development of synovial hypertrophy and synovial fibro-
blast hyperplasia and induction of local glucocorticoid
generation within synovium are needed for a significant
paracrine effect of inflammation on bone. The data also
suggest that in clinical situations where glucocorticoids
are used to target synovial inflammation the detrimental
effects of this therapy on bone could be mediated by direct
effects through glucocorticoid receptor signalling in osteo-
blasts or indirectly through glucocorticoid receptor signal-
ling in synovial fibroblasts.
Figure 3 The effect of endogenous glucocorticoids +/- 11b-hydroxysteroid dehydrogenase (11b-HSD) enzyme inhibitor on DKK1
expression. (A) Effect of various glucocorticoids on DKK1 mRNA expression in synovial fibroblasts (FLS). Cortisone caused a significant increase
in DKK1 mRNA, an effect blocked by the 11b-HSD1 inhibitor glycyrrhetinic acid (GE). (B) Effect of glucocorticoids on DKK1 protein secretion in
FLS and dermal fibroblasts (DF). (C) Sensitisation of DKK1 secretion by FLS to the effects of cortisone (E) by pretreatment with TNFa for
48 hours. *P < 0.05, **P < 0.01 relative to control. Results shown are the combined duplicates of four separate FLS lines.
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The involvement of glucocorticoids in mechanisms to
switch off tissue repair is not surprising. Glucocorticoids
have anti-anabolic and catabolic effects in a range of tis-
sues. An increase in the levels of glucocorticoids within
the tissue through an increase in the activity of the
hypothalamo-pituitary-adrenal axis is an important protec-
tive response. Adrenal insufficiency in humans or animals
leads to a dramatic reduction in ability to withstand
inflammatory stress [19]. Within bone, glucocorticoid
signalling in synovial fibroblasts may provide a useful way
of uncoupling bone resorption from formation during
joint disease. Without an ability to temporarily uncouple
formation from resorption there is a risk of aberrant,
uncoordinated bone deposition that could be detrimental
to the function of the joint. Importantly, abnormal osteo-
phyte formation has been recently reported in HSD11B1
knockout mice in response to inflammatory arthritis [20].
At sites of bone remodelling, there was clearly abnormal
Figure 4 Effects of glucocorticoids or TNFa on Wnt-related gene expression. (A and B) Effect of glucocorticoid treatment (100 nM
dexamethasone) or TNFa (10 ng/ml) on expression of Wnt-related genes (n = 96) was examined using a targeted microarray. Genes with the
greatest fold change are shown (the effect of TNFa on DKK1 and FRZB expression was not significant). A full list of the genes included in the
array and their full gene titles is given in Additional file 1, Table S1. (C) Real-time PCR validation of changes in mRNA expression for FRZB and
WNT2 in response to dexamethasone (DEX) or TNFa. *P < 0.05, **P < 0.01 relative to control. Results shown are the combined results of three
separate FLS lines.
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excessive formation of new bone that was greatest adjacent
to the site of synovial tissue inflammation. This is despite
the gene for DKK1 being intact, and there being higher
levels of circulating TNFa and endogenous corticosterone
during inflammation, in this model. All these factors
would normally be expected to result in a greater impair-
ment of bone formation in knockout animals than wild
types. The high corticosterone levels also demonstrate that
the phenotype observed is unlikely to be related to an
alteration of systemic glucocorticoid levels since excessive
bone formation occurred despite the higher circulating
glucocorticoid levels.
Previous studies have linked variation in the expression
of DKK1 by synovial fibroblasts to rheumatic diseases
associated with excessive bone formation, primarily AS
[13,21] although abnormal expression of the osteocyte-
specific protein (and Wnt signalling inhibitor) sclerostin
has also been described [22]. We observed no difference
in the ability of glucocorticoids to induce DKK1 in a lim-
ited number of patients with AS. However, it must be
borne in mind that the excessive formation of bone in
this condition is normally restricted to the axial spine.
The reason for the axial predisposition to AS is unclear
but it is possible that this reflects a difference in the regu-
lation or expression of 11b-HSD1 in the spinal tissues.
Synovial tissue is likely to differ between the peripheral
and central joints and 11b-HSD1 expression in some cell
types demonstrates regional variation [9]. Polymorphic
markers within the HSD11B1 gene have been linked to
differences in bone density and fracture risk [23] and
could provide tools to examine for differences in bone
manifestation of disease in patients with chronic inflam-
matory conditions.
Conclusions
These data show that local glucocorticoid metabolism
has an important role in the regulation of bone remo-
delling. The 11b-HSD1 enzyme is thus a potential thera-
peutic target for treating disorders characterised by
uncoupling of bone formation from resorption.
Figure 5 Role of local glucocorticoid generation in inflammatory changes in bone. Schematic illustration of the mechanism by which
synovial inflammation interacts with local generation of active glucocorticoids to modulate Wnt signalling in osteoblasts.
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Additional material
Additional file 1: Table S1. Complete list of genes included in array:
Complete list of genes included in array examining the impact of TNFa
and glucocorticoid treatments on Wnts, Wnt inhibitors and Wnt-
regulated genes. Shaded rows indicates genes where expression was
significantly impacted on by either TNFa or dexamethasone (DEX). Array
data have been submitted to the Gene Expression Omnibus (GEO)
repository and given the designation GSE37520.
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